Alpha 2.0
Login Register
» Articles » PMID: 2966980

Preclinical Studies with Trimetrexate: a Review of Conclusions and Unanswered Questions

Overview
Journal Semin Oncol
Specialty Oncology
Date 1988 Apr 1
PMID 2966980
Citations 6
Authors
R C Jackson
W R Leopold
K L Hamelehle
D W FRY
Affiliations
Soon will be listed here.
Citing Articles

Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.

Garcia A, Leichman L, Baranda J, Pandit L, Lenz H, Leichman C Int J Gastrointest Cancer. 2004; 34(2-3):79-86.

PMID: 15361639 DOI: 10.1385/IJGC:34:2-3:079.

Clinical pharmacokinetics and pharmacology of trimetrexate.

Marshall J, DeLap R Clin Pharmacokinet. 1994; 26(3):190-200.

PMID: 8194282 DOI: 10.2165/00003088-199426030-00003.

A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.

Grochow L, Noe D, Ettinger D, Donehower R Cancer Chemother Pharmacol. 1989; 24(5):314-20.

PMID: 2758561 DOI: 10.1007/BF00304765.

Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.

Carlson R, Doroshow J, Odujinrin O, Flam M, Malec M, Lamborn K Invest New Drugs. 1990; 8(4):387-9.

PMID: 2150672 DOI: 10.1007/BF00198597.

Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial.

Witte R, Elson P, Bryan G, Trump D Invest New Drugs. 1992; 10(1):51-4.

PMID: 1535065 DOI: 10.1007/BF01275483.